Literature DB >> 22450707

Drugs for tuberculosis.

.   

Abstract

RECOMMENDATIONS: The standard treatment for latent tuberculosis is nine months of isoniazid taken daily, or twice weekly under direct observation by a healthcare worker. Taking isoniazid and rifapentine once weekly for 12 weeks under direct observation is an alternative for patients >12 years old. Initial therapy for patients with active or suspected tuberculosis should include isoniazid, rifampin,pyrazinamide and ethambutol until susceptibility is known. In patients with drug-susceptible pulmonary tuberculosis, the continuation phase of treatment should be a combination of isoniazid and either rifampin or rifapentine, taken for 4 or 7 months depending on risk factors. Confirmed multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis should be treated with directly observed therapy in collaboration with a clinician familiar with management of these conditions. Treatment must include at least 4 drugs to which the organism is susceptible; the duration of therapy should usually be 18-24 months. Directly observed therapy by a healthcare worker should be offered to all patients with active tuberculosis to minimize treatment failure, relapse and the emergence of drug resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450707

Source DB:  PubMed          Journal:  Treat Guidel Med Lett        ISSN: 1541-2784


  2 in total

1.  Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.

Authors:  Xiaolei Pan; Li Wang; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

2.  Characterization, activity, and computer modeling of a molecular inclusion complex containing rifaldazine.

Authors:  Qunyou Tan; Dan He; Mingjun Wu; Lin Yang; Yong Ren; Juan Liu; Jingqing Zhang
Journal:  Int J Nanomedicine       Date:  2013-02-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.